ArticleIndian journal of sexually transmitted diseases and AIDS2013
Getting to zero: Possibility or propoganda?
Article in Indian journal of sexually transmitted diseases and AIDS, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of LCAT and Apo A-I in Newly Diagnosed HIV Patients.Indian journal of clinical biochemistry : IJCB · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The world is now in the fourth decade of a pandemic that united all the nations more than any other calamities or policies. The numbers with relation to HIV are falling consistently. Unfortunately the funding is also decreasing. In the current uncertain economic environment, the Joint United Nations Programme on HIV and AIDS (UNAIDS) has set a very ambitious target of reducing HIV to zero by 2015. There are strategies that are good and cost-effective and, if used appropriately, will give remarkable results. No new innovations have recently been discovered related to HIV. More molecular level studies are needed besides strengthening the existing strategies. We need money for all these activities and it should not stop coming. The paper reviews the success of HIV program in India and also foresees the challenges lying ahead of us in "getting to zero."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.